drugset / Trial / NCT02812862

Cardiac Effects of Spiolto®/Respimat® in Patients With Congestive Heart Failure and COPD

NCT02812862

Phase 4 Withdrawn RWTH Aachen University
NaSingle-groupOpen-labelOther

Summary

The aim of this study is to evaluate the pulmonary and cardiac effects of the LABA / LAMA combination Tiotropium / Olodaterol therapy in patients suffering from both congestive heart failure and chronic obstructive pulmonary disease.

Timeline

Start
2016-08
Primary completion
2017-08
Completion
2018-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Olodaterol Small molecule
Subject Tiotropium Other / unclassified